| CURIS INC. DL -,01 |
| USA |
| Gesundheit |
| US2312693094 / A3ETJD |
| CUS0 (Frankfurt) / CRIS (NASDAQ) |
| FRA:CUS0, ETR:CUS0, CUS0:GR, NASDAQ:CRIS |
| - |
| https://www.curis.com/ |
|
Curis Inc. is a biotechnology company focused on discovering and developing drug candidates for treating human cancers. The company's lead program centers on emavusertib (CA-4948), an orally available small molecule inhibitor targeting IRAK4 and FLT3..
>Volltext.. |
| 19.4 Mio. EUR |
| 16.49 Mio. EUR |
| 8.04 Mio. EUR |
| -27.86 Mio. EUR |
| -6.45 Mio. EUR |
| -1.02 EUR |
| 1.38 Mio. EUR |
| 4.31 Mio. EUR |
| -23.15 Mio. EUR |
| 0.36 |
| -23.7% |
| 84.6% |
| - |
| - |
| - |
| - |
| CURIS |
| 07.05.26 |
|